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Relationship of dose of hemodialysis and cause-specific mortality. A
number of studies have found a relationship of lower all-cause mortality
risk for ESRD patients treated with increasing dose of dialysis. The
objective of this study was to determine the relationship of delivered dose
of dialysis with cause-specific mortality. Data from the USRDS Case Mix
Adequacy Study, which includes a national random sample of hemodial-
ysis patients, were utilized. To minimize the contribution of unmeasured
residual renal function, the sample used in this analysis (N = 2479)
included only patients on dialysis for one year or more. Cox proportional
hazards models, stratified for diabetes, were used to analyze the effect of
delivered dose of dialysis (measured and reported by both Kt/V and URR)
on major causes of death and withdrawal from dialysis, adjusting for other
covariates including demographics, comorbid diseases present at start of
study, functional status, laboratory values and other dialysis parameters.
Patient follow-up for mortality was censored at the earliest of time of
transplantation, 60 days after a switch to peritoneal dialysis or at the time
of data abstraction. For each 0.1 higher Kt/V, the adjusted relative risk of
death due to coronary artery disease was 9% lower (RR = 0.91, P < 0.05),
due to other cardiac causes was 12% lower (RR = 0.88, P < 0.01), due to
cerebrovascular disease (CVD) was 14% lower (RR =0.86,P < 0.05),due
to infection was 9% lower (RR 0.91, P = 0.05), and due to other known
causes was 6% lower (RR = 0.94, P < 0.05). There was no statistically
significant relationship of KtIV and risk of death among patients who died
of malignancy(RR = 0.84, P 0.10) or among patients whose death cause
was missing (RR = 0.95, P = 0.41). The risk of withdrawal from dialysis
prior to death due to any cause was 9% lower (RR = 0.91, P < 0.05) for
each 0.1 higher KtIV. The relationships of delivered dose of dialysis, as
measured by URR, and cause-specific mortality were essentially similar in
relative magnitude and statistical significance as the relationships ob-
served using Kt/V as the measurement of dialysis dose, with the exception
that the relationship was less significant for cerebrovascular disease and
withdrawal from dialysis. The relationship of dialysis dose with risk of
death due to each cause of death category except other cardiac causes and
"other" causes appeared to be of greater magnitude and of greater
statistical significance among diabetics than non-diabetics. These results
indicate that low dose of dialysis is not associated with mortality due to just
one isolated cause of death, but rather is due to a number of the major
causes of death in this population. This study is consistent with hypotheses
that low doses of dialysis may promote atherogenesis, infection, malnu-
trition and failure to thrive through a variety of pathophysiologic mecha-
nisms. Further study is necessary to confirm these results and to test
hypotheses that are developed.
Despite the availability of renal replacement therapy, the
mortality of patients with end-stage kidney failure (ESRD) re-
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mains high. This may be due to, among other factors, the
underlying disease causing the patient's renal failure and its
associated comorbidities, it may be an effect of the therapy itself,
or it may be due to inadequate renal replacement therapy.
In the early days of dialysis, treatment adequacy was felt to be
represented by the absence of the uremic syndrome. However,
concerns about subclinical manifestations of uremic toxicity lead-
ing to adverse long-term consequences prompted nephrologists to
further evaluate the amount of dialysis that should be delivered. A
number of methods were developed to quantify dialysis and to
assure that "enough" was delivered [1-8]. Of these, the parameter
Kt/V (a product of total clearance and treatment time per urea
distribution volume) [8], which originated from the 1982 National
Cooperative Dialysis Study (NCDS) [9], has been the most widely
accepted technique for the quantification of the hemodialysis
prescription and for measurement of the delivered hemodialysis
dose. The NCDS has also been the most influential study in
alerting the dialysis community to the importance of quantifica-
tion of dialysis. Analyses by Gotch and Sargent [8] showed that a
Kt/V of 0.8 or less was associated with a high degree of uremic
morbidity Their analyses also suggested that there was little
dose-res(onse within the range of Kt/V of 0.9 to 1.5, and that
providing doses of dialysis above Kt/V of 1.0 (25% higher than
Kt/V of 0.8 or "inadequate dialysis") were of no apparent clinical
value. However, reappraisal of edited data from the NCDS by
Keshaviah suggested a curvilinear relationship of Kt/V and mor-
bidity [101.
In a national random sample of prevalent dialysis patients, the
USRDS has found that an approximate log-linear relationship of
decreasing mortality with increased dose of dialysis exists within
the range of a Kt/V of 0.8 to 1.4 [11]. This is also supported by
other studies which have examined the effect of dialysis dose on
mortality [12—16].
Little is known regarding the causes of death associated with
inadequate dialysis. The number of deaths among the patients
studied in the NCDS was too small to explore this question. Our
speculation a priori was that a low dose of dialysis leads to
malnutrition and failure to thrive, possibly resulting in withdrawal
from dialysis. Previous work by Collins et al [17] also suggested
that infectious mortality is reduced at higher doses of dialysis.
Analysis of cause of death statistics may generate hypotheses
regarding the mechanisms by which dialysis dose may affect
mortality. We therefore undertook a study to determine the effect
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of delivered dose of dialysis on specific causes of death in a
national sample of prevalent hemodialysis patients.
Methods
Data
The data used in these analyses was a subset of the United
States Renal Data System's (USRDS) Case Mix Adequacy Study
dataset that was supplemented with information from the USRDS
database.
The Case Mix Adequacy Study was a USRDS Special Study in
which data on a national sample of hemodialysis patients was
collected to study the relationship of dialysis dose, dialyzer
membrane, and dialyzer flux on patient outcomes. A random
sample of 7,096 patients who were alive on December 31, 1990
was drawn from 523 in-center hemodialysis facilities. A systematic
sampling methodology (based on dialysis unit size) was used to
identify a sample of dialysis units, from which patients were
subsequently randomly selected (proportional to unit size) based
on the last two digits of their social security number. This process
was undertaken to ensure patient and provider samples that were
nationally representative. All patients in the study were entitled to
Medicare payment of dialysis services.
Data were abstracted retrospectively from the patients' dialysis
facility medical records by the 18 ESRD Networks under a
contract with the Health Care Financing Administration (HCFA)
of the U.S. Department of Health and Human Services, using a
data collection form that was developed and tested by the USRDS
Coordinating Center, the National Institute of Diabetes and
Digestive and Kidney Diseases and the Health Care Financing
Administration (HCFA). The study start date was December 31,
1990 for patients who developed ESRD prior to January 1, 1990,
and one month after the first dialysis treatment for patients
incident during 1990. Data were abstracted by ESRD Network
personnel between April 1, 1992 and March 31, 1993. Patient
identifiers, health insurance information, information on patient
history, the presence or absence of a variety of comorbid health
conditions occurring within 10 years prior to study start date,
dialysis information, psychosocial information and laboratory data
were abstracted from each patient's dialysis facility medical
record. Data on changes in patient status occurring after the study
start date, including transplantation, switch to peritoneal dialysis,
recovery of renal function, and death, were obtained using data in
the 18 ESRD Network databases. (A copy of the data abstraction
form for this study is published in the USRDS 1994 Annual Data
Report, Appendix B.) In order to be consistent in the extent to
which we captured all outcomes (deaths, transplant, switch to
PD), follow-up for each patient was continued from study start
date to the date that the abstraction form was completed.
The USRDS database, which contains longitudinal data on all
Medicare ESRD patients in the United States from 1977 to the
present, was linked to the Case Mix Adequacy Dataset. The
USRDS contains data on approximately 93% of all patients
treated for ESRD in the U.S. Most of the USRDS database data
are derived from the HCFA Program Management and Medical
Information System. The supplemental information used in our
analyses included race, primary cause of ESRD, date of first
dialysis service, date of death, date of any kidney transplant and
cause of death. The cause of death data are received by HCFA, by
means of a Death Notification Form (HCFA-2746-U3) which lists
59 categories for cause of death. For each death occurring among
the U.S. Medicare ESRD population, HCFA requires the primary
cause of death to be reported by the patient's renal physician; the
physician must also indicate whether the patient withdrew from
dialysis prior to death. The USRDS database includes data from
the Death Notification Form as well as a "missing" cause of death
category for those patients who, by means of the Social Security
System and/or hospital discharge records, are known to have died
but for whom no Death Notification form was received. The
USRDS data used in this analysis were based on a May 31, 1993
update of HCFA file sources. As mentioned previously, each
patient was followed to the date of Case Mix Adequacy Study data
abstraction.
Analytical methods
Data on a subset of prevalent patients from the USRDS Case
Mix Severity Study, for whom Kt/V and URR could be calculated,
were included in this analysis [18]. Incident patients (defined as
persons having their first treatment for ESRD in 1990) were
excluded to yield a prevalent sample among whom the residual
renal function was likely to be minimal or absent. Although this
represents a great improvement over a previous USRDS study of
delivered dialysis therapy wherein only 10% of patients had a pre-
and post-dialysis BUN, in this dataset only 68% of patients had a
pre- and post-dialysis BUN necessary to calculate Kt/V and URR.
The remainder patients were excluded. As there is no easy way to
compare dose among patients dialyzing with different weekly
frequencies, the main analyses were also limited to patients
receiving three dialysis sessions per week.
Patients in the original dataset were therefore systematically
excluded per the following criteria: inability to link with existing
USRDS data files primarily due to incorrect Medicare ID (N =
348), non-correspondence of ESRD start dates (N = 61), recovery
of renal function (N = 31), age less than 15 years (N = 18),
incident in 1990 (N = 1805), absence of post-dialysis BUN
necessary to calculate Kt/V and URR (N = 2148), Kt/V less than
0.4 or greater than 2.0 (N = 12), data missing for on more than
half of the comorbid conditions evaluated (N = 9), missing data
abstraction date (N = 11), missing data on dialyzer membrane(N = 24), and dialyzed more or less than three dialysis sessions
per week (N = 151). Missing values for numeric variables were set
to the mean of the overall group. For categorical variables,
missing values were considered not to be present.
The independent variable of interest was delivered dose of
dialysis. Several investigators have developed techniques to com-
pute Kt/V based on pre-dialysis and post-dialysis serum urea
measurements [19-21] in order to simplify its measurement. For
this analysis, Kt/V was calculated from the following formula [22].
Delivered KtJV = — ln(R — 0.008 * t) + (4 — 3.5R) * IJF/W
where R = post-dialysis/pre-dialysis blood urea nitrogen, t =
dialysis hours, UF = pre-post dialysis weight change (change in
weight occurring during the dialysis session) and W = post-
dialysis weight. The mean value of several Kt/V readings (on
average 3) over a six months period (study start date 3 months)
for each patient was used in these analyses. The timing of the
post-dialysis urea sample was assumed to be immediately follow-
ing termination of dialysis. Therefore these Kt/V values represent
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Table 1. List of baseline covariate values for the study population
(N 2479)
-
Variable
Mean (SD)
or percent
Demographics
Mean age, years (so) 57.9 (15.7)
Race % white (vs. non-white) 57.1
Gender % female 49.6
Cause of ESRD % diabetes (vs. all others) 24.7
Prior failed transplant % yes 10.0
Mean duration of ESRD at study start date, years (SD) 4.6 (3.8)
Comorbid conditions (% yes)
Diabetes (history of and/or nephropathy) 36.3
Coronary artery disease (history of)a 47.5
Left ventricular hypertrophy (history of) 43.4
Congestive heart failure (history of) 42.9
Cardiomegaly (on X-ray)
Peripheral vascular disease (history of)'
48.9
22.8
Pulmonary disease (history of) 12.4
Neoplasm (history of)C 9.1
Smoking (history of) 17.4
Body mass index kg/rn2 24.5 (5.9)
Functional status
Ambulation % unable to independently ambulate 7.5
Dialysis parameters
Dialyzer membrane % Biocornpatible' 35.4
(vs. unmod cellulose)
Dialysate % acetate 7.7
Lab values, mean (SD)
Albumin g/dl 3.8 (0.4)
Hematocrit % 29.3 (4.7)
Creatinine mg/dl 11.9 (3.8)
All of these variables were included in all reported models.
The study population includes patients prevalent > 1 year for whom
Kt/V and URR could be calculated, receiving 3 dialysis sessions per week.
a Includes history of coronary heart disease or coronary artery disease,
coronary artery bypass surgery, angioplasty or abnormal angiographyb Includes history of peripheral vascular disease, amputation, absent
pulses or claudication
C Excludes basal cell and squamous carcinoma of the skin
Includes modified cellulose and synthetic membranes (vs. unmodified
cellulose)
the so-called "single-pool" kinetics and do not account for re-
bound. The relationships of the individual components compris-
ing KtIV [221 (R [expressed as URR = 1 — R], dialysis time and
UF/W) as well as sessions per week with cause-specific mortality,
were also analyzed among the larger sample of patients (N =
2630), which included those patients dialyzed less than or greater
than three times per week. URR, which is generally more
interpretable by clinicians, was used rather than R as URR is also
used as a technique to measure the dose of dialysis [23].
Patients treated with differing doses of dialysis may also be
different in terms of demographic, comorbidity and other baseline
characteristics as well as other treatment parameters. If these
characteristics can affect cause of death, independent of the dose
of dialysis, this may lead to problems with selection bias in our
analysis. Analyses were therefore adjusted for all covariates listed
in Table 1. Demographic characteristics, functional status, dialysis
parameters and laboratory data reflect characteristics present at
the time of the study start date. The comorbid conditions are
those present within 10 years prior to the study start date, as
recorded in the patient's dialysis facility medical record. The
comorbid conditions selected for inclusion were those found to be
important mortality risk factors based on prior analyses and on
clinical judgment. Each of the covariates was a significant predic-
tor of risk for at least one cause of death.
The dependent variables were time to cause-specific death and
to all-cause death, as well as time to death in the setting of
withdrawal from dialysis. The 59 cause of death categories
reported to HCFA were collapsed into the seven categories shown
in Table 2.
Cox proportional hazards regression techniques [24] were used
to estimate the relationship of dose of dialysis with death due to
each cause of death category (7 models) as well as with death
preceded by withdrawal from dialysis (1 model). For each model,
patients were censored (that is, removed from the analysis) at the
earliest of time of transplantation, 60 days after a switch to
peritoneal dialysis, study completion date (date of data abstrac-
tion), or at the time of death due to all causes other than the one
of interest for any given model. These models were designed to
test the null hypotheses that the risk of death due to each
individual cause is not different for differing doses of dialysis.
Previous studies have suggested that the proportional hazards
assumption is violated in studies of mortality in dialysis patients as
death rates of diabetics and non-diabetics are not proportional
over time [25, 26]. In this study of prevalent patients, the diabetes
by time interaction (from SAS version 6.07 [27]), which tests the
proportionality assumption, was of borderline significance for
all-cause mortality but not for any of the specific causes of death.
In view of this possible violation of the assumptions of the Cox
model, the main analyses were stratified by diabetes (defined as
presence of diabetic nephropathy or any history of diabetes). The
stratified Cox model allows for non-proportional hazard rates for
diabetic and non-diabetic patients, and then calculates a single
parameter estimate for each covariate [27]. To determine if the
effect of dose of dialysis varied significantly by presence of
diabetes, the interaction of diabetes and Kt/V was also tested. In
addition, models were subsequently estimated for diabetics and
non-diabetics separately.
An additional analysis was performed including the interaction
between dose of dialysis and presence of coronary artery disease
(CAD) in the model, to determine if the effect of dose of dialysis
on deaths due to CAD varied among patients with or without a
history of coronary artery disease at the time of the study start
date. Likewise, an additional analysis was performed including the
interaction of dose of dialysis and presence of a cardiac abnor-
mality to determine if the effect of dose of dialysis for deaths due
to "other cardiac" causes varied by the presence or absence of a
documented history of congestive heart failure, left ventricular
hypertrophy, or cardiomegaly on chest X-ray within 10 years of
the study start date.
As cardiac arrest was the proximate cause of death regardless of
other antecedent causes, for the main models the cause of death
"cardiac arrest" was considered in the "other" category. A sepa-
rate analysis was also performed in which this category was
considered under the category "other cardiac."
KtIV values at the extremes are less likely to be accurate
measures of chronic delivered dose of dialysis [281. Low Kt/V
values are less likely to be reflective of chronic therapy, as they
would be likely to invoke increases in dialysis prescription. High
Kt/V values are more likely to be associated with high efficiency
dialysis and may be overestimates of delivered dose as the Kt/V
values calculated for these analyses did not account for urea
rebound. To determine the impact of our decision to include
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MI, acute
Atherosclerotic heart disease
Valvular heart disease
Cardiomyopathy
Cardiac ariythmia
Hyperkalemia
Pericarditis
PuIm edema, exogenous fluid
Cerebrovascular
Septicemia, vascular access
Septicemia, peritonitis
Septicemia, PVD/gangrene
Septicemia, other
Pulmonary infection, bacterial
Pulmonary infection, fungal
Pulmonary infection, other
Viral infection, cmv
Viral infection, other
TB
AIDS
Infection, other
Hepatitis B
Other viral hepatitis
Fungal peritonitis
Malignancy Malignant disease, immunosup
Malignant disease
Cardiac arrest
Pulmonary embolus
Liver-drug toxicity
Cirrhosis
Polycystic liver disease
Liver failure, cause unknown
GI hemorrhage
Hemorrhage from vascular
access
Other hemorrhage
Mesenteric infarction
Pancreatitis
Perforation of peptic ulcer
Perforation of bowel
Bone marrow depression
Dementia
Seizures
Diabetic coma, hypo/hyperglyc
COPD
Complications of surgery
Ischemic brain/anoxic
encephalopathy
Air embolism
Accident related to treatment
Accident unrelated to treatment
Suicide
Drug overdose-street drugs
Drug overdose
Cachexia
Other identified cause
Unknown
Missing Cause of death missing
Total deaths
patients with a wide range of Daugirdas corrected KtIV values
from 0.4 to 2.0, we also performed a supplementary Cox propor-
tional hazards model including only patients with Kt/V values of
0.6 to 1.6.
12 Results
27 4 The mean age of the 2479 prevalent dialysis patients included in
i this study was 57.9 years (Table 1). Fifty-seven percent of patients
27 4 were white, 49.6% were female, 36% were diabetic and in 24.7%
62 8 diabetic nephropathy was reported as the cause of ESRD. The
16 mean duration of prior ESRD therapy in this prevalent sample
4 1 was 4.6 years. Ten percent of patients had a previous failed
transplant. The frequency of comorbid conditions and mean
38 values of lab data are shown in Table 1. Approximately 35% of
8 1 patients were using modified cellulosic or synthetic membranes
2 and the remainder were using unmodified cellulosic membranes.
40 5 Kt/V values were approximately normally distributed, with a mean
16 2 and median value of 1.11. Five percent and 1% of patients had a
0 0 KtIV value greater than 1.54 and 1.73, respectively, and 5% and
2 a 1% had a Kt/V less than 0.72 and 0.59, respectively. During
follow-up, there were 736 deaths, 162 patients were transplanted
0 0 and 20 patients were transferred to peritoneal dialysis.
2 a The relative mortality risk for each of the covariates associated
3 a with each cause of death is shown in Table 3. These covariates
g were all controlled for in each analyses evaluating the adjusted
0 0 relative mortality risk (RR) for the effect of dose of dialysis on
cause-specific mortality (Table 4). The RR for KtIV represents
the average relative mortality risk associated with each increase in
KtIV of 0.1 units based on a log-linear model, stratified for
137 19 diabetes and adjusted for all other covariates listed in Table 1. As
0 0 reported elsewhere, all-cause mortality risk was 8% lower (RR =
3 a 0.92, P < 0.001) for each 0.1 higher Kt/V [11]. The risk of death
0 0 due to coronary artery disease was 9% lower (RR = 0.91, P <i a 0.05), due to other cardiac causes was 12% lower (RR =0.88, P <
0.01), due to cerebrovascular disease was 14% lower (RR = 0.86,
P < 0.05), due to infection was 9% lower (RR = 0.91, P = 0.05)
2 a and due to other known causes was 6% lower (RR = 0.94, P <
7 1 0.05). There was no relationship of Kt/V and risk of death due to
malignancy (RR = 0.84, P = 0.10) or among patients whose death
4 1 cause was missing (RR = 0.95 P = 0.41). The relationships of
0 0 dose of dialysis and each cause of death did not appear to be
3 a statistically different from each other in this analysis (as the
a
confidence intervals were not exclusive). However, this may be the
1 result of has insufficient statistical power in view of the relatively
2 a small number of deaths in each specific cause of death category.
8 1 The risk of withdrawal from dialysis prior to death (due all causes
combined) was 9% lower (RR = 0.91, P < 0.05) for each 0.1
higher Kt/V.
4 In a separate analysis which included patients dialyzed for any
3 a number of sessions per week (not limited to 3 times weekly), when
0 0 number of sessions per week and the components compromising
2 a Kt/Vwere disaggregated and entered into the model as individual
45 covariates, sessions, dialysis time, and UF/W were not indepen-
42 6 dent predictors of cause-specific mortality (P > 0.05). One
57 8 exception is that receiving two sessions per week was predictive ofdeath due to neoplasm, suggesting that patients with neoplasm are
736 100 dialyzed less frequently, as 16 of the 22 patients dying of neoplasm
had a malignancy at study start. Only URR was predictive of
specific causes of death in a manner similar in relative magnitude
and significance to the relationships observed with KtIV except
Table 2. Percent distribution and categorization of causes of death on
Death notification Form (HCFA-2746) for study patients
Number Percent
of of
Category Cause of death deaths deaths
Coronary Artery
Disease
Cardiac, other
Cerebrovascular
Infection
Other
a < 1% of deaths
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Table 3. Relative mortality risk° for demographic, comorbid, laboratory and treatment covariates for each cause of death
Coronary
All artery Other Cerebrovascular
Covariate causes disease cardiac disease Infection Malignancy
Withdrawal
Other Missing from dialysis
Demographics
Age (per 10 years) 1.26° 130d 1.16° 1.23° 1.38° 1.34 1.19° 2.08 1.6°
Female (vs. male) 0.87° 0.72 0.61° 0.97 0.82 2.24c 1.05 0.45° 1.80
White (vs. non-white) 1.32° 1.39 1.25 1.47 1.30 1.02 l.36' 21d 2.23°
Duration of ESRD (per year) 1.01 1.02 1.00 1.02 1.05 0.90 1.03° 0.94 1.32
Prior failed transplant 0.71° 1.05 0.66 0.75 0.00 0.00
Comorbid conditions1'
0.65° 2.25 0.62
Inability to ambulate 1.62° 1.64' 2•02d 2.02 214d 0.67
Peripheral vascular disease 132d 2.12° 1.20 1.69 1.50° 0.79
1.43° 3.12°
1.04 0.84
1.41
1.19
COPD 1.44° 0.95 1.44 1.18 1.60° 2.00 1.60° 0.81 1.16
Cardiornegaly 1.42° 1.56c 1.44c 1.20 1.24 0.84
Neoplasm l.34' 1.14 1.02 1.03 1.03 25.8°
1.50° 0.96
1.07 0.84
1.09
1.67c
Coronary artery disease 1.07 1.80' 0.96 1.02 0.84 0.45°
Smoker 1.06 1.11 1.18 0.73 1.05 380d
0.98 1.30
0.92 1.23
1.07
1.30
Congestive heart failure 1.14 1.10 1.45° 0.97 0.83 1.22 1.20 0.95 1.40°
Body mass index (per kg/rn2) 0.97° 0.85 0.93" 0.93" 0.97 1.02 0.95° 0.96 0.93
Missing comorbidity 1.32° 1.41° 1.24 1.37 1.40 1.17 1.26' 1.74° 1.43c
Laboratory values
Albumin (per 1 g/dl) 0.66° 0.72 0.77 0.75 0.92 0.67
Hernatocrit (per 1%) 0.98" 1.03 0.98 0.99 0.96° 0.98
Creatinine (per 1 mg/dl) 0.96° 0.95 0.97 1.02 0.96 0.94
0.63e 0.30°
0.97' 0.98
0.95" 0.96
0.36°
1.01
0.97
Dialysis parameters
Acetate (vs. Bicarbonate) 1.25° 1.17 0.82 1.42 1.24 2.03
Biocompatible Membrane 077d 0.55" 0.98 0.96 0.69 1.13
0.91 2.23°
0.88 0.91
0.59
0.54"
° Models were stratified by diabetes.
b Refer to Table 1 for further description of these covariates
"P < dp < "P < 0.001
Table 4. Effect of dose of dialysis on cause-specific mortality
Kt/V URR
RR per RR per95% Confidence
Cause of death N PE° 0.1 Kt/V" Pvalue" interval PE 5% URR"
95% Confidence
P value° interval
All causes 736 —0.87 0.92 <0.001 0.887, 0.949 —0.03 0.879 <0.001 0.838, 0.922
Coronary artery disease 114 —0.98 0.91 0.03 0.830, 0.990 —0.03 0.875 0.03 0.773, 0.990
Other cardiac 118 —1.24 0.88 <0.01 0.812, 0.961 —0.04 0.836 <0.01 0.745, 0.938
Cerebrovascular 38 —1.55 0.86 0.04 0.736, 0.996 0.04 1.195 0.09 0.969, 1.473
Infection 90 —0.95 0.91 0.05 0.824, 1.003 —0.03 0.876 0.06 0.763, 1.007
Malignancye 22 —1.79 0.84 0.10 0.675, 1.036 —0.04 0.803 0.17 0.584, 1.103
Other known cause 297 —0.61 0.94 0.02 0.893, 0.992 —0.02 0.914 0.01 0.855, 0.978
Missing 57 —0.52 0.95 0.41 0.839, 1.075 —0.02 0.890 0.18 0.749, 1.058
736
Withdrawal 112 —0.89 0.91 <0.05 0.839, 0.998 —0.02 0.896 0.09 0.788, 1.018
a Parameter estimate
"RR, relative mortality risk per 0.1 unit higher Kt/V stratified for diabetes and adjusted for all other covariates listed in Table 1
°Tests HO:RR = 1.00 (no effect of Kt/V); Ha:RR' 1.00 (two tailed)d RR = relative mortality risk per 5% higher URR stratified for diabetes and adjusted for all other covariates listed in Table 1
° 16 of 22 deaths due to malignancy occured in patients with malignancy prior to start of study
that the relationship with deaths due to cerebrovascular disease
was less significant (P = 0.09 compared toP = 0.05). Similarly the
relationship of URR and withdrawal from dialysis prior to death
was less significant than the corresponding relationship with Kt/V.
The risk estimates and levels of significance are also listed in
Table 4.
The relationship of dose of dialysis, as measured by Kt/V, and
cause specific mortality was evaluated among diabetics and non-
diabetics separately. Although the relationships of KtIV with
cause specific mortality for diabetics and nondiabetics were not
significantly different from each other (P > 0.1), these analyses
revealed that the correlation of dialysis dose with each cause of
death category except "other cardiac causes" and "other causes"
appeared to be of greater magnitude and of greater statistical
significance among diabetics.
The relationship of dose of dialysis with death due to coronary
artery disease was similar among patients with and without a
documented history of coronary artery disease at baseline. Like-
wise, the risk of death due to other cardiac causes did not vary
among patients with or without pre-existing cardiac disease.
10.0
9.0
8.0
7.0
5.0 All causes 4.2
4.0
_______ —
3
0) RR=O.63
- 3.0 ('=0.04 RR=0.84
20 1.4
('=0.02
-
. 0.9
a)o 1.0
0.0 I I I I
0th Card. CAD Infect. CVD Other
9.3
30
25
20
15
10
5
0
3.2
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3.1
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Fig. 1. Estimated death rate per 100 dialysis
patient years due to all causes (insert) and due to
each cause of death among patients receiving Kt/
V of 0.9 ) and 1.2 (Eli). The death rates are
adjusted for covariates outlined in Table 1. The
RRs are the adjusted relative risks of death due
to each cause for Kt/V 1.2 compared to 0.9 (z
Kt/V 0.3). P values represent the likelihood of a
RR being different from 1.00 by chance.
Abbreviations are: CVD, cerebrovascular;
CAD, coronary artery disease; Infect., infection;
Oth.Card., cardiac causes other than those due
to coronary artery disease; Other, all other
known causes.
In an analyses wherein deaths due to "cardiac arrest" were
included in the "other cardiac" cause of death category, the
relationship of Kt!V and death due to "other cardiac" causes was
weaker but still statistically significant (RR = 0.92, P < 0.01).
When a more restricted range of Kt/V was evaluated (0.6 to 1.6
rather than 0.4 to 2.0), there was no meaningful or systematic
differences between analyses.
As an illustration, Figure 1 shows an example of the impact of
differing doses of dialysis, according to the cause-specific RR from
the main model. The adjusted death rates per 100 dialysis patient
years for each cause of death are compared among patients
receiving Kt/V 0.9 and patients receiving Kt/V 1.2 ( = 0.3).
Based on the linear model, the RR is assumed to remain the same
for any Kt/V difference of 0.3.
Discussion
A number of studies have found a relationship of decreasing
all-cause mortality with increased dose of dialysis [11-14, 16]. This
study of cause-specific mortality suggests that lower doses of
dialysis do not effect mortality through one isolated cause, but
rather through a number of the major causes of death in the
dialysis population. The relationship is strongest and is significant
for deaths due to coronary artery disease, other cardiac causes
and infection. These associations appear to be robust as they are
consistent in all models including one where the range of deliv-
ered KtIV was less inclusive. Deaths due to the category "other
causes" are significantly associated with dose of dialysis but the
magnitude of effect was less. The relationship of dose of dialysis
and deaths due to cerebrovascular disease varied depending on
the method used to measure dose. This lack of consistency may be
due to the large statistical variation resulting from the small
number of deaths in this cause of death category. Deaths due to
"neoplasm" and "missing cause of death" were not significantly
associated with dose of dialysis.
Coronary artery and cerebrovascular disease
To our knowledge, the relationship of dose of dialysis and
deaths due to coronary artery disease has not been previously
described. A comparison of delivered dialysis dose between
patients with and without prior documented CAD showed the
mean, median and quartile values of Kt/V to be similar in the two
groups, suggesting that there was no preselection for patients with
prior documented CAD to receive less dialysis.
Coronary artery is a major cause of death in patients with
ESRD treated with dialysis. The association of long-term dialysis
and accelerated atherosclerosis was first proposed by Lindner et al
[29] in 1974 and subsequently supported by several other investi-
gators [30—32]. However, although it is agreed that death rates
from ischemic heart disease among ESRD patients in any age
group are increased by a factor of 5 to 20 compared to the general
population, some have intimated that this may represent the
development of atheroma pre-ESRD [33—37], which then be-
comes clinically apparent during dialysis therapy. This would
suggest that it is uremia, not the dialysis procedure, that has an
adverse cardiac effect. Perhaps there are atherogenic factors
present in patients with renal failure that are increasingly removed
with higher doses of dialysis.
Atherosclerosis is a shared pathogenic feature of cerebrovas-
cular and coronary artery disease. The major risk factors for
atherosclerosis in the general population include increased age,
male sex, hypertension, hyperlipidemia, family history, smoking
and diabetes. Although the risk factors for atherosclerosis in the
ESRD population have not been well-defined and may differ from
the general population, it is reasonable to assume that there is
some similarity [381.
Hypertension is common among dialysis patients [39]. Charra
et al [40] have found higher mean arterial pressures among
patients treated with lower doses of dialysis and they attribute this
to inadequate removal of intravascular volume. Higher levels of
Kt/V have been shown to be associated with longer duration of
dialysis treatment times [41] and maybe associated with the use of
membranes which require a volumetric ultrafiltration control
system on the dialysis machine. Both these features may allow
greater opportunity for fluid removal and better subsequent
control of blood pressure. Thus, the dose of dialysis may exert its
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effect on reducing CAD and CVD deaths through better control
of blood pressure.
Hyperlipidemia is another potentially important risk factor of
atherogenesis in ESRD patients. Dialyzed patients have been
shown to have elevated triglycerides, VLDL, and lipoprotein(a),
as well as decreased HDL and apolipoprotein CII levels [38—41],
all of which may be associated with increased atherogenic risk.
The observation of decreasing risk of cerebrovascular and coro-
nary artery deaths among patients receiving increasing Kt/V in
this study may be explained in part if these lipid abnormalities
vary favorably with increasing dose of dialysis. Recent studies
have found improvements in lipid profiles associated with high-
flux dialysis including lower triglyceride and increased HDL
concentrations as well as increased lipoprotein lipase activity
[42—47]. Although attributed to the membrane type, the observed
higher dose of dialysis associated with high flux membranes may
partially explain these findings.
Uremic abnormalities which vary with dose of dialysis may also
play a mechanistic role in the development of atherosclerosis and
help explain the current study observations. It has been proposed
that in patients with renal failure, urea itself contributes to the
carbamylation of LDL cholesterol, producing a substance which
has been shown to be cytotoxic. This cytotoxicity may in turn
contribute to the development of atherosclerosis in patients with
renal failure [48]. In addition, Cohen, Patel and Kornhauser [49]
suggested that several nitrogen retention products, notably me-
thionine, guanidino acids and homocysteine are agents which
produce endothelial damage, thereby initiating the sequence of
events leading to atherosclerosis. It is conceivable that increasing
the dose of dialysis might increase clearance of these products,
thereby reducing the risk of accelerated atherosclerosis. Similarly
the increased elimination of a hypothetical lipoprotein lipase
inhibitor present in uremic plasma may be responsible [46, 50]. In
our study the association of dose of dialysis with deaths due to
CAD and CVD appeared to be greater among diabetics than
non-diabetics, although these were not significantly different from
each other. Perhaps a reduction in one atherosclerotic risk factor
is more important when another risk factor (diabetes) is present,
suggesting potential synergistic relationships.
Other cardiac causes
The category of "other cardiac causes" includes deaths due to
to cardiac arrhythmia (51%), cardiomyopathy (25%), hyperkale-
mia (14%), valvular heart disease (< 5%), pericarditis (< 5%)
and pulmonary edema (< 5%). Several of these causes, particu-
larly the cardiac dysrrhythmias, are frequently a result of coronary
artery disease thus several of the pathogenetic mechanisms pre-
viously discussed may also be implicated here. Higher doses of
dialysis may also achieve better metabolic control (such as less
hyperkalemia, acidosis) and thus be associated with less arrhyth-
mogenicity. Pericarditis, although rare as a cause of death, is
known to be a consequence of inadequate clearance of uremia
toxins and to resolve with improved clearance. Deaths due to the
causes in this heterogenous category may be associated with dose
of dialysis to varying degrees and be the result of several different
mechanisms.
Infection
The risk of death due to infection appears to be less with higher
doses of dialysis as measured by both Kt/V and URR. Collins et
al [17] examined infection and cardiac mortality among ESRD
patients older than 60 years treated with conventional and high-
dose dialysis and found that high dose of dialysis (Kt/V> 1.4) had
more impact on risk of death due to infection than on overall and
cardiac deaths among diabetics. Uremia is characterized by an
enhanced susceptibility for infectious diseases, in part due to
defective phagocytic function. It has been proposed that higher
doses of dialysis may optimize the elimination of solutes that
negatively affect phagocytic function [51]. Lindsay et a! have
shown that increasing Kt/V results in increases in protein cata-
bolic rate, suggesting that inadequate dialysis may result in poor
appetite and malnutrition [52, 53]. Poor nutritional status has
been associated with infectious complications in hemodialysis
patients [541.
Withdrawal from dialysis
The risk of withdrawal from dialysis prior to death due to any
cause also appears to be lower with higher doses of dialysis as
measured by Kt/V. Recently the USRDS has reported that over
40% of patients who withdraw from dialysis reportedly do so
because of chronic failure to thrive [41]. We speculate that
inadequate dialysis contributes to malnutrition which in turn may
promote withdrawal from dialysis. Malnutrition, as measured by
abnormally low serum albumin, is known to be a common
problem among dialysis patients and a strong predictor of mor-
tality among this population [40—52]. Further studies are needed
to explore this possible relationship. An additional 35% of
patients who withdraw from dialysis prior to their death are
reported to withdraw due to acute medical complications [41].
Given the high frequency of cardiac and infectious complications
in dialysis patients, the mechanisms discussed previously by which
dose of dialysis may be associated with these conditions may also
contribute to the risk of withdrawal from dialysis.
This study was not experimental in design, and therefore the
observed relationships are not necessarily causal. Despite adjust-
ments for a variety of demographic, comorbid, laboratory and
treatment-related variables, there may exist remaining unmea-
sured differences in baseline characteristics or differences in the
treatment of patients who receive lower versus higher doses of
dialysis, which may bias or confound our results. For example,
patients who receive higher doses of dialysis may also receive
better care in other areas of dialysis delivery or in their general
medical care.
A relatively large number of prevalent patients were excluded
from analysis because data needed to calculate delivered Kt/V
were not available. A comparison of baseline covariates (demo-
graphics, duration of prior ESRD, comorbid conditions) between
patients included and excluded in the analysis, using logistic
regression, found no significant differences between these patients
with the exception that those excluded were more likely to be
white, to have a lower serum albumin and to be missing data on
one or more comorbid conditions. There was also no significant
difference in survival between those included and excluded.
Another possible limitation of this study is that the cause of
death is reported by renal physicians in a manner that has not
been standardized. Different physicians may use different defini-
tions/criteria for assigning each cause of death. Study results may
be compromised if there was a selective difference in degree of
misclassification for patients with different dose of dialysis. The
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advantages of utilizing these data are likely to outweigh this
possible limitation.
Death notification forms for some patient deaths occurring in
early 1993 may not be in the USRDS data source used for this
study, contributing in part to the "missing" cause of death
categoiy. As the distribution of causes of death may vary by time
on dialysis, there may be selective undercounting of these later
deaths (occurring after 2 years) by categorizing them as missing. It
is unlikely that the relationship of KtIV and specific causes of
death would be greatly influenced; however, this remains a
possible limitation.
A sample of prevalent patients who were receiving dialysis at
least one year was used for this study in an attempt to exclude
patients with significant residual renal function, which might
compromise the estimates of delivered KtIV [53]. The results of
this study can therefore only be rightfully generalized to similar
populations. Prevalent samples include patients with a wide range
in duration of ESRD; this may act as a confounding variable if
ESRD duration is associated with dose of dialysis and also
independently affects mortality risk. However, our analyses did
not find duration of ESRD alone, nor any interactions of duration
of ESRD with other demographic covariates, to be independent
predictors of mortality, when other covariates were included in
the models.
The method used to compute Kt!V in this study assumes a
single pool for urea with variable volume. This assumption is not
strictly correct as rebound in BUN has been shown to occur,
particularly with high-efficiency dialysis. Timing of the post-
dialysis specimen is therefore important. The same is true if access
or cardiopulmonary recirculation is present. In this study there
was no standardization of the timing of the post-dialysis BUN.
Therefore the use of a single pool model may overestimate the
true Kt/V for some patients. The relationships of dose and
cause-specific mortality may therefore be even stronger than
observed in this study.
This study has found that the risk of death for a number of
cause of death categories was higher among patients receiving
smaller doses of dialysis. The relationship of Kt!V with mortality
appeared to be strongest and statistically significant for deaths due
to CAD, other cardiac causes and infection. The risk of death due
to other causes and withdrawal from dialysis also correlated
inversely with dialysis dose; however, the strength of the associa-
tion and the level of significance were less for these causes. This
study puts forth the hypotheses that compared to higher doses of
dialysis, low doses of dialysis may promote atherogenesis, infec-
tion, malnutrition and failure to thrive through a variety of
pathophysiologic mechanisms, and result in increased deaths due
to many causes. These hypotheses require confirmation, ideally in
studies with an experimental design, large sample size, and
standardization of methods assigning cause of death. Evaluating
the association of dose of dialysis with cause-specific morbidity
(such as hospitalizations) may also further the understanding of
the mechanisms by which dose of dialysis affects mortality.
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